RARE logo

RARE Total Liabilities

Annual Total Liabilities

$1.22 B
+$22.65 M+1.90%

December 31, 2023


Summary


Performance

RARE Total Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRAREbalance sheetmetrics:

Quarterly Total Liabilities

$1.18 B
-$1.48 M-0.13%

September 30, 2024


Summary


Performance

RARE Quarterly Total Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherRAREbalance sheetmetrics:

Total Liabilities Formula

Total Liabilities = Current Liabilities + Long-Term Liabilities

RARE Total Liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+1.9%-1.8%
3 y3 years+100.9%+114.9%
5 y5 years+998.6%+675.8%

RARE Total Liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+102.7%-2.6%+101.6%
5 y5-yearat high+152.3%-2.6%+145.9%
alltimeall timeat high>+9999.0%-2.6%>+9999.0%

Ultragenyx Pharmaceutical Total Liabilities History

DateAnnualQuarterly
Sep 2024
-
$1.18 B(-0.1%)
Jun 2024
-
$1.19 B(+1.6%)
Mar 2024
-
$1.17 B(-4.0%)
Dec 2023
$1.22 B(+1.9%)
$1.22 B(+0.8%)
Sep 2023
-
$1.21 B(+2.0%)
Jun 2023
-
$1.18 B(+1.7%)
Mar 2023
-
$1.16 B(-2.5%)
Dec 2022
$1.19 B(+98.9%)
$1.19 B(+3.8%)
Sep 2022
-
$1.15 B(+78.9%)
Jun 2022
-
$642.55 M(+9.4%)
Mar 2022
-
$587.61 M(-2.0%)
Dec 2021
$599.84 M(-0.9%)
$599.84 M(+8.8%)
Sep 2021
-
$551.13 M(+2.0%)
Jun 2021
-
$540.27 M(-0.5%)
Mar 2021
-
$543.18 M(-10.2%)
Dec 2020
$605.18 M(+25.6%)
$605.18 M(+0.5%)
Sep 2020
-
$602.19 M(-2.6%)
Jun 2020
-
$618.45 M(-0.9%)
Mar 2020
-
$623.99 M(+29.5%)
Dec 2019
$481.73 M(+335.4%)
$481.73 M(+215.5%)
Sep 2019
-
$152.68 M(+9.7%)
Jun 2019
-
$139.14 M(+15.0%)
Mar 2019
-
$121.03 M(+9.4%)
DateAnnualQuarterly
Dec 2018
$110.65 M(+3.1%)
$110.65 M(+7.9%)
Sep 2018
-
$102.55 M(+0.5%)
Jun 2018
-
$102.05 M(+8.9%)
Mar 2018
-
$93.69 M(-12.7%)
Dec 2017
$107.30 M(+61.0%)
$107.30 M(+54.4%)
Sep 2017
-
$69.49 M(+2.1%)
Jun 2017
-
$68.09 M(+18.7%)
Mar 2017
-
$57.34 M(-14.0%)
Dec 2016
$66.65 M(+134.0%)
$66.65 M(+12.4%)
Sep 2016
-
$59.28 M(+55.8%)
Jun 2016
-
$38.06 M(+10.8%)
Mar 2016
-
$34.36 M(+20.7%)
Dec 2015
$28.48 M(+118.7%)
$28.48 M(+12.3%)
Sep 2015
-
$25.37 M(+6.9%)
Jun 2015
-
$23.73 M(+61.2%)
Mar 2015
-
$14.72 M(+13.0%)
Dec 2014
$13.02 M(+36.5%)
$13.02 M(+12.2%)
Sep 2014
-
$11.61 M(+22.1%)
Jun 2014
-
$9.50 M(+35.9%)
Mar 2014
-
$6.99 M(-26.7%)
Dec 2013
$9.54 M(+139.9%)
$9.54 M(+28.3%)
Sep 2013
-
$7.44 M(+87.1%)
Dec 2012
$3.98 M(+167.6%)
$3.98 M
Dec 2011
$1.49 M
-

FAQ

  • What is Ultragenyx Pharmaceutical annual total liabilities?
  • What is the all time high annual total liabilities for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical annual total liabilities year-on-year change?
  • What is Ultragenyx Pharmaceutical quarterly total liabilities?
  • What is the all time high quarterly total liabilities for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical quarterly total liabilities year-on-year change?

What is Ultragenyx Pharmaceutical annual total liabilities?

The current annual total liabilities of RARE is $1.22 B

What is the all time high annual total liabilities for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high annual total liabilities is $1.22 B

What is Ultragenyx Pharmaceutical annual total liabilities year-on-year change?

Over the past year, RARE annual total liabilities has changed by +$22.65 M (+1.90%)

What is Ultragenyx Pharmaceutical quarterly total liabilities?

The current quarterly total liabilities of RARE is $1.18 B

What is the all time high quarterly total liabilities for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high quarterly total liabilities is $1.22 B

What is Ultragenyx Pharmaceutical quarterly total liabilities year-on-year change?

Over the past year, RARE quarterly total liabilities has changed by -$21.89 M (-1.81%)